Muscle is metabolically active tissue—losing it makes weight loss harder to sustain
A large-scale review from the University of Copenhagen, presented at the European Congress on Obesity in Istanbul in May 2026, surfaces a quiet paradox at the heart of modern weight-loss medicine: the most powerful tools for shedding pounds — obesity drugs and bariatric surgery — also claim the steepest toll on the muscle and bone that sustain long-term health. Where diet and exercise preserve the body's metabolic architecture, the faster paths extract a hidden biological cost, reminding us that in medicine, as in life, the swiftness of a solution rarely tells the whole story of its consequences.
- Obesity drugs and surgery produce dramatically greater weight loss than lifestyle changes, but strip away two to five times more muscle and bone in the process — a trade-off that has gone largely unexamined until now.
- Surgery patients lose an average of 9.14 kilograms of fat-free mass and drug users lose 4.75 kilograms, compared to just 1.80 kilograms for those relying on diet and exercise — numbers that carry real consequences for metabolism, mobility, and independence.
- The loss of lean tissue is not merely cosmetic: reduced muscle mass lowers resting calorie burn, raises the risk of weight regain, and increases vulnerability to falls, fractures, and functional decline — concerns that compound the existing burdens of obesity.
- Researchers are not calling for abandoning drugs or surgery, but are urgently pressing for structured exercise programs to be built into every weight-loss pathway as a non-negotiable safeguard for muscle and bone.
A sweeping meta-analysis from the University of Copenhagen, presented at the European Congress on Obesity in Istanbul, has uncovered an uncomfortable trade-off embedded in the most aggressive weight-loss approaches: obesity drugs and bariatric surgery, while highly effective at reducing overall body weight, also cause significantly greater losses of muscle, bone, and organ tissue than diet and exercise alone.
The review examined 21 randomized controlled trials involving 1,334 people who had lost at least 10 percent of their body weight through lifestyle changes, incretin-based medications such as semaglutide, or bariatric surgery. Led by Professor Signe Torekov and PhD student Lærke Bruun Madsen, the team tracked what happened to fat-free mass — the lean tissue responsible for burning calories and sustaining metabolic function — across each method.
The contrasts were stark. People using diet and exercise lost an average of 1.80 kilograms of fat-free mass, representing just 14.3 percent of their total weight loss. Drug users lost 4.75 kilograms of lean tissue — 31.5 percent of their total loss. Surgery patients lost 9.14 kilograms, or 32.9 percent. The drugs and surgery delivered larger overall results, averaging 15.9 and 27.4 kilograms of total weight lost respectively, against 11.6 kilograms for lifestyle intervention. But the body paid for those results in lean tissue.
The stakes extend well beyond aesthetics. Muscle burns more calories at rest than fat; its loss slows metabolism and makes sustained weight management harder. Bone density governs fracture risk and physical independence. For people already navigating the complications of obesity, these are not peripheral concerns.
The researchers stop short of discouraging drugs or surgery — both remain legitimate, often life-changing interventions. Their argument is structural: exercise programs must be integrated into every weight-loss approach, by any method, to protect the lean tissue the body would otherwise sacrifice. Losing weight, they suggest, is only part of the equation. What is preserved in the process shapes health for years to come.
Researchers at the University of Copenhagen have completed a sweeping review of weight-loss studies that reveals an uncomfortable trade-off: the most aggressive approaches to shedding pounds—obesity drugs and surgery—also strip away significantly more muscle and bone than the slower path of diet and exercise alone.
The analysis, presented at the European Congress on Obesity in Istanbul in May, examined 21 randomized controlled trials involving 1,334 people who had lost at least 10 percent of their body weight through one of three methods: lifestyle changes, incretin-based medications like semaglutide, or bariatric surgery. The researchers, led by Professor Signe Torekov and PhD student Lærke Bruun Madsen, measured what happened to fat-free mass—the muscle, bone, and organ tissue that burns calories and keeps metabolism running—during each type of weight loss.
The numbers tell a stark story. People who lost weight through diet and exercise shed an average of 1.80 kilograms of fat-free mass. Those taking obesity drugs lost 4.75 kilograms. Those undergoing surgery lost 9.14 kilograms. Put another way: when someone using diet and exercise lost weight, only 14.3 percent of that loss came from muscle and bone. For drug users, that figure jumped to 31.5 percent. For surgery patients, it reached 32.9 percent. The drugs and surgery worked—they produced larger overall weight losses, averaging 15.9 kilograms and 27.4 kilograms respectively, compared to 11.6 kilograms for lifestyle intervention. But the cost was paid in lean tissue.
Why this matters goes beyond vanity or strength. Muscle tissue burns more calories at rest than fat tissue does. Bone density affects mobility and fracture risk. When people lose substantial amounts of fat-free mass, their metabolic rate drops, making it harder to keep weight off long-term. They also face increased risk of falls, fractures, and functional decline—the ability to climb stairs, carry groceries, live independently. These are not abstract concerns for people already managing obesity and its complications.
The emergence of incretin-based drugs has transformed obesity treatment in recent years. These medications work powerfully and reliably, producing weight losses that diet and exercise alone rarely achieve. Yet their very effectiveness has raised questions about what gets lost in the process. Surgery, too, remains a legitimate option for people with severe obesity, but it is irreversible and carries surgical risks. The new analysis suggests that neither approach is metabolically neutral—both extract a price in lean tissue that deserves attention.
The researchers are not arguing against drugs or surgery. Rather, they are calling for a shift in how these interventions are deployed. Structured exercise programs should accompany weight loss by any method, they argue, to preserve the muscle and bone that the body would otherwise sacrifice. The implication is clear: losing weight is not enough. How you lose it, and what you preserve while doing so, shapes your health trajectory for years to come.
Citações Notáveis
Diet and exercise interventions were associated with the smallest reductions in fat-free mass, whereas incretin-based obesity drugs and obesity surgery were associated with substantially greater proportional losses of fat-free mass.— Professor Signe Torekov and colleagues, University of Copenhagen
A Conversa do Hearth Outra perspectiva sobre a história
Why does it matter if someone loses muscle along with fat, as long as the weight comes off?
Because muscle is metabolically active tissue. It burns calories even when you're sitting still. When you lose muscle, your resting metabolism drops, which makes it harder to maintain weight loss long-term. You end up in a worse position than when you started.
So diet and exercise are better than drugs and surgery?
Not necessarily better overall. Surgery and drugs produce much larger weight losses, which matters for people with severe obesity. But they come with a hidden cost—you're losing more of the tissue that keeps your metabolism running. It's a trade-off, not a simple win.
Can you reverse muscle loss after weight-loss surgery?
Yes, but it requires deliberate effort. The research suggests that adding structured exercise to any weight-loss approach—whether it's drugs, surgery, or lifestyle changes—can help preserve muscle during the process. Prevention is easier than recovery.
Why haven't we known this before?
We have, in pieces. But this meta-analysis brings together 21 studies and shows the pattern clearly. It's the first time someone has systematically compared all three approaches side by side using the same measurement standards.
What should someone do if they're considering obesity medication?
The research doesn't say avoid it. It says: if you're taking the drug, also commit to exercise. Don't treat weight loss as a passive process where the medication does all the work. The medication handles the appetite and metabolism; exercise handles preserving the muscle that keeps your metabolism healthy long-term.